In a patient with primary sclerosing cholangitis without elevated liver enzymes or alkaline phosphatase who is on adalimumab (Humira) and mesalamine, what is the next drug to try if adalimumab fails?

Next Treatment After Adalimumab Failure in PSC

There is no established next-line drug therapy for PSC itself when adalimumab fails, as biologics and immunosuppressives are not recommended for routine PSC treatment. Your focus should shift to managing the underlying IBD with alternative biologics while recognizing that PSC progression will likely continue independently 1.

Key Clinical Context

Your patient presents an unusual scenario - they have PSC with normal liver enzymes and alkaline phosphatase, which is atypical for PSC. This raises important questions:

• Confirm the PSC diagnosis is accurate (cholangiographic findings should be present) 1
• The normal biochemistry suggests either very early disease or possible small duct PSC
• The adalimumab was likely prescribed for IBD, not PSC

Treatment Algorithm

For the IBD Component (Primary Focus):

If adalimumab fails for IBD control:

1. Vedolizumab - α4β7 integrin blocker, IBD-specific mechanism

   • Effective for IBD in PSC patients (31.2% endoscopic response rate) 2
   • Critical caveat: Associated with worsening liver enzymes in PSC patients 2
   • Monitor liver biochemistry closely if used

2. Infliximab - Alternative anti-TNF agent

   • May reduce alkaline phosphatase modestly 1
   • Retrospective data shows moderate effectiveness for PSC-IBD 1

3. JAK inhibitors or IL-12/23 inhibitors - Emerging options

   • Limited PSC-specific data but effective for IBD 3

For the PSC Component:

No biologic therapy is recommended 1. The 2022 EASL guidelines explicitly state:

• Corticosteroids/immunosuppressives/biologics are not suggested for routine PSC treatment 1
• Multiple agents tested (anti-TNF antibodies, vedolizumab, etc.) have shown disappointing results 1
• One retrospective study suggested adalimumab may have a "possible positive signal" but this requires further investigation 1

Important Caveats

Safety Concerns with Continued Biologics:

From the FDA label, continuing any TNF blocker carries risks 4:

• Serious infections (tuberculosis, fungal infections)
• Malignancies (lymphoma, skin cancers)
• Higher risk in patients >65 years or on concomitant immunosuppressants
• Screen for latent TB before switching biologics

The Mesalamine Question:

Continue mesalamine for IBD maintenance - it's safe and can be used alongside biologics 1, 4.

Monitoring Strategy:

Even with normal biochemistry now:

• Monitor alkaline phosphatase, bilirubin, and transaminases every 3-6 months
• Annual MRCP to assess biliary disease progression
• Colonoscopy surveillance (increased colorectal cancer risk in PSC-IBD)
• Consider hepatobiliary malignancy screening if disease progresses

Clinical Reality

The harsh truth: No medication has been shown to improve transplant-free survival or reduce disease-related morbidity/mortality in PSC 3. Your treatment goal is IBD control while monitoring for PSC progression, dominant strictures, and malignancy development. If liver biochemistry remains normal, the patient may have indolent disease, but this doesn't change the lack of effective PSC-specific therapy.

Bottom line: Switch to vedolizumab or infliximab for IBD management, but watch liver enzymes carefully with vedolizumab. Do not expect any biologic to modify PSC disease course.